Literature DB >> 19204418

The potential of a placebo/nocebo effect in pharmacogenetics.

S B Haga1, L R Warner, J O'Daniel.   

Abstract

Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic test results on drug response. Placebo and nocebo-like effects may be possible due to the suggestive nature of pharmacogenetic information that a drug will or will not likely lead to improved health outcomes. For example, pharmacogenetic testing could provide further reassurance to patients that a given drug will be effective and/or cause minimal side effects. However, pharmacogenetic information could adversely affect drug response through negative expectations that a drug will be less than optimally effective or cause an adverse response, known as a nocebo-like effect. Therefore, a patient's perceived value of testing, their understanding of the test results, and the manner in which they are communicated may influence therapeutic outcome. As such, physicians should consider the potential effect of pharmacogenetic test results on therapeutic outcome when communicating results to patients. Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204418      PMCID: PMC2738872          DOI: 10.1159/000189628

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  54 in total

Review 1.  Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications.

Authors:  A M O'Connor; V Fiset; C DeGrasse; I D Graham; W Evans; D Stacey; A Laupacis; P Tugwell
Journal:  J Natl Cancer Inst Monogr       Date:  1999

2.  Placebos, placebo effect, and the response to the healing situation: the evolution of a concept.

Authors:  Y G Papakostas; M D Daras
Journal:  Epilepsia       Date:  2001-12       Impact factor: 5.864

3.  Placebo and opioid analgesia-- imaging a shared neuronal network.

Authors:  Predrag Petrovic; Eija Kalso; Karl Magnus Petersson; Martin Ingvar
Journal:  Science       Date:  2002-02-07       Impact factor: 47.728

4.  Response expectancies in placebo analgesia and their clinical relevance.

Authors:  Antonella Pollo; Martina Amanzio; Anna Arslanian; Caterina Casadio; Giuliano Maggi; Fabrizio Benedetti
Journal:  Pain       Date:  2001-07       Impact factor: 6.961

5.  The language of uncertainty in genetic risk communication: framing and verbal versus numerical information.

Authors:  M Welkenhuysen; G Evers-Kiebooms; G d'Ydewalle
Journal:  Patient Educ Couns       Date:  2001-05

6.  Behavioral conditioning of immunosuppression is possible in humans.

Authors:  Marion U Goebel; Almuth E Trebst; Jan Steiner; Yu F Xie; Michael S Exton; Stilla Frede; Ali E Canbay; Martin C Michel; Uwe Heemann; Manfred Schedlowski
Journal:  FASEB J       Date:  2002-12       Impact factor: 5.191

Review 7.  Nonspecific medication side effects and the nocebo phenomenon.

Authors:  Arthur J Barsky; Ralph Saintfort; Malcolm P Rogers; Jonathan F Borus
Journal:  JAMA       Date:  2002-02-06       Impact factor: 56.272

8.  Risk in numbers--difficulties in the transformation of genetic knowledge from research to people--the case of hereditary cancer.

Authors:  L Sachs; A Taube; C Tishelman
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

9.  Information presentation and decisions to enter clinical trials: a hypothetical trial of hormone replacement therapy.

Authors:  J A Wragg; E J Robinson; R J Lilford
Journal:  Soc Sci Med       Date:  2000-08       Impact factor: 4.634

10.  How the doctor's words affect the patient's brain.

Authors:  Fabrizio Benedetti
Journal:  Eval Health Prof       Date:  2002-12       Impact factor: 2.651

View more
  5 in total

Review 1.  Nocebo in headaches: implications for clinical practice and trial design.

Authors:  Dimos D Mitsikostas
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

2.  Pharmacogenomics and public health.

Authors:  D Veenstra; W Burke
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

3.  Genomic Essentialism: Its Provenance and Trajectory as an Anticipatory Ethical Concern.

Authors:  Maya Sabatello; Eric Juengst
Journal:  Hastings Cent Rep       Date:  2019-05       Impact factor: 2.683

4.  The nocebo effect of drugs.

Authors:  Sara Planès; Céline Villier; Michel Mallaret
Journal:  Pharmacol Res Perspect       Date:  2016-03-17

5.  Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study.

Authors:  Cathelijne H van der Wouden; Stefan Böhringer; Erika Cecchin; Ka-Chun Cheung; Cristina Lucía Dávila-Fajardo; Vera H M Deneer; Vita Dolžan; Magnus Ingelman-Sundberg; Siv Jönsson; Mats O Karlsson; Marjolein Kriek; Christina Mitropoulou; George P Patrinos; Munir Pirmohamed; Emmanuelle Rial-Sebbag; Matthias Samwald; Matthias Schwab; Daniela Steinberger; Julia Stingl; Gere Sunder-Plassmann; Giuseppe Toffoli; Richard M Turner; Mandy H van Rhenen; Erik van Zwet; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Pharmacogenet Genomics       Date:  2020-08       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.